BOUNDLESS BIO, INC. Deferred Offering Costs
BOUNDLESS BIO, INC. (BOLD) had Deferred Offering Costs of $0 as of 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2025-03-27
- 2024-12-31: Deferred Offering Costs $0.00.
- 2024-09-30: Deferred Offering Costs $0.00.
- 2024-06-30: Deferred Offering Costs $0.00.
- 2024-03-31: Deferred Offering Costs $5.30M.
| Period end | Deferred Offering Costs |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 |
| 2024-03-31 | $5.30M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $2.20M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |